


37. Gillison ML, Blumenschein GR, Fayette J, et al: Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/M patients and updated safety and efficacy. J Clin Oncol 35:6019, 2017


39. Escudier B, Tannir N, McDermott D, et al: CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (NIVO + sunitinib) (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups Presented at the European Society for Medical Oncology 2017 Congress.
REFERENCES


68. US Food and Drug Administration. FDA approves olaparib tablets for maintenance treatment in ovarian cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm


REFERENCES

80. Shi Q, Sobero AF, Shields AF, et al: Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage II colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol 35, 2017 (suppl; abstr LBA1)